Marcin Bula
Impact in
- Infectious Diseases top 2%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
-
- Vaccine Coverage and Hesitancy
Papers in
-
- SARS-CoV-2 and COVID-19 Research 10
- COVID-19 Clinical Research Studies 2
- Parasitic Diseases Research and Treatment 1
-
- Pharmacogenetics and Drug Metabolism 1
- Antibiotics Pharmacokinetics and Efficacy 1
- Co-authors
- Paola Motta (1 shared paper)Jesús Reiné (1 shared paper)Daniela Mulari Ferreira (1 shared paper)William W. Hope (1 shared paper)Elena Mitsi (1 shared paper)Jamie Rylance (1 shared paper)Shampa Das (1 shared paper)Asad Ullah (1 shared paper)
- Journals
- The Lancet Infectious Diseases (4 papers)Journal of Infection (3 papers)Diagnostic Molecular Pathology (1 paper)Antimicrobial Agents and Chemotherapy (1 paper)Open Forum Infectious Diseases (1 paper)
- Partner nations
- United KingdomUnited StatesJapan
In The Last Decade
Marcin Bula
12 papers receiving 862 citations
Marcin Bula's Hit Papers
Peers
Comparison fields: 5 of 55
- Infectious Diseases 741
- Health 36
- Molecular Medicine 23
- Toxicology 8
- Virology 6
Countries citing papers authored by Marcin Bula
This map shows the geographic impact of Marcin Bula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcin Bula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcin Bula more than expected).
Fields of papers citing papers by Marcin Bula
This network shows the impact of papers produced by Marcin Bula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcin Bula. The network helps show where Marcin Bula may publish in the future.
Co-authors
The 25 scholars most cited alongside Marcin Bula, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Hit paper breakdown → | 2021 | 382 |
| 2 | 2022 | 138 | |
| 3 | 2021 | 97 | |
| 4 | 2022 | 65 | |
| 5 | 2022 | 52 | |
| 6 | 2023 | 47 | |
| 7 | 2022 | 38 | |
| 8 | 2020 | 32 | |
| 9 | 2023 | 30 | |
| 10 | 2016 | 3 | |
| 11 | 2024 | 2 | |
| 12 | 2023 | 1 | |
| 13 | 2025 | 0 |
About Marcin Bula
Marcin Bula is a scholar working on Infectious Diseases, Pharmacology, Pharmacology, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 13 papers that have together received 887 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Antibiotics Pharmacokinetics and Efficacy (1 paper) and Parasitic Diseases Research and Treatment (1 paper). The work is most often cited by research in Infectious Diseases (741 citations), Health (36 citations), Molecular Medicine (23 citations), Toxicology (8 citations) and Virology (6 citations). Marcin Bula has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Paola Motta, Jesús Reiné, Daniela Mulari Ferreira, William W. Hope, Elena Mitsi, Jamie Rylance, Shampa Das, Asad Ullah, Patrick Vélicitat and Helen C. Hill. Their work appears in journals such as The Lancet Infectious Diseases, Journal of Infection, Diagnostic Molecular Pathology, Antimicrobial Agents and Chemotherapy and Open Forum Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.